Milford Funds Ltd. Invests $7.95 Million in Novo Nordisk A/S $NVO

Key Points

• Milford Funds Ltd. opened a new position in Novo Nordisk, buying 156,298 shares valued at about $7.95 million in the fourth quarter. Other institutional investors also added to or started stakes, and hedge funds now own about 11.54% of the stock.
• Momentum around Novo Nordisk improved after UK regulators approved the daily Wegovy pill, the first GLP-1 weight-loss tablet approved in the country. The approval could expand the company’s obesity franchise beyond injections and create a new growth channel.
• Despite the positive catalyst, Novo Nordisk is facing some headwinds, including an IT security incident involving unauthorized access to internal systems and concerns that some U.S. employers may reduce GLP-1 obesity-drug coverage in 2027. Analysts currently rate the stock a Hold overall.

Milford Funds Ltd. acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 156,298 shares of the company's stock, valued at approximately $7,952,000.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Godfrey Financial Associates Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after acquiring an additional 260 shares in the last quarter. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $28,000. Maseco LLP bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NVO. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, February 23rd. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 target price for the company. Weiss Ratings lowered Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 22nd. Zacks Research raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Finally, Kepler Capital Markets lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus target price of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $43.90 on Friday. The stock has a fifty day simple moving average of $42.28 and a two-hundred day simple moving average of $46.00. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a market cap of $196.02 billion, a price-to-earnings ratio of 10.31, a price-to-earnings-growth ratio of 3.93 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.